A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Recruiting

Phase 1

Phase 2

GV20-0251, PembrolizumabA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Sponsor:

GV20 Therapeutics

Code:

NCT05669430

Conditions

Solid Tumor, Adult

Refractory Cancer

Endometrial Carcinoma (EC)

Squamous Head and Neck Carcinoma

pMMR/MSS Adenocarcinoma of the Colon or Rectum

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

GV20-0251

GV20-0251 and Pembrolizumab [KEYTRUDA®]

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-25. This information was provided to ClinicalTrials.gov by GV20 Therapeutics on 2025-02-13.